Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 20;10(7):911.
doi: 10.3390/pathogens10070911.

Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol

Marie Pouquet  1 , Dorine Decarreaux  1   2   3 , Pol Prévot-Monsacré  1 , Corentin Hervé  1 , Andréas Werner  4 , Brigitte Grosgogeat  5   6   7 , Hélène Blanché  8 , Pascaline Rabiega  9 , Julien Laupie  7 , Fabienne Kochert  4 , Nathalie Abraham  9 , Jean-Marc Sebaoun  8 , Xavier de Lamballerie  3 , Remi Charrel  3 , Cecile Souty  1 , Ibrahima Camara  1 , Jeanne Pergeline  1 , Harold Noël  10 , Caroline Guerrisi  1 , Sylvie van der Werf  11   12 , Fabrice Carrat  1 , Thomas Hanslik  1   13   14 , Thierry Blanchon  1 , Alessandra Falchi  2
Affiliations

Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol

Marie Pouquet et al. Pathogens. .

Abstract

Background: The protocol study will focus on the seroprevalence of IgG antibodies to SARS-CoV-2 achieved by vaccination and/or natural protection as well as the history, symptoms, and risk factors for SARS-CoV-2 in four primary health-care workers (PHCWs) and their household contacts in metropolitan France.

Methods: Here, we propose a protocol for a nationwide survey to determine the seroprevalence of IgG antibodies to SARS-CoV-2 achieved by vaccination and/or natural protection in four PHCW populations (general practitioners, pediatricians, pharmacists and assistants, and dentists and assistants) and their household contacts. Participants will be included from June to July 2021 (Phase 1) among PHCW populations located throughout metropolitan France. They will be asked to provide a range of demographic and behavioral information since the first SARS-CoV-2 wave and a self-sampled dried blood spot. Phase 1 will involve also a questionnaire and serological study of PHCWs' household contacts. Seroprevalence will be estimated using two ELISAs designed to detect specific IgG antibodies to SARS-CoV-2 in humoral fluid, and these results will be confirmed using a virus neutralization test. This study will be repeated from November to December 2021 (Phase 2) to evaluate the evolution of immune status achieved by vaccination and/or natural protection of PHCWs and to describe the history of exposure to SARS-CoV-2.

Keywords: SARS-CoV-2; household; primary health-care workers; seroprevalence; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Participant pathway.
See this image and copyright information in PMC

References

    1. Garcia-Basteiro A.L., Moncunill G., Tortajada M., Vidal M., Guinovart C., Jiménez A., Santano R., Sanz S., Méndez S., Llupià A., et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat. Commun. 2020;11:3500. doi: 10.1038/s41467-020-17318-x. - DOI - PMC - PubMed
    1. Belingheri M., Paladino M., Riva M.A. Beyond the assistance: Additional exposure situations to COVID-19 for healthcare workers. J. Hosp. Infect. 2020;105:353. doi: 10.1016/j.jhin.2020.03.033. - DOI - PMC - PubMed
    1. Galanis P., Vraka I., Fragkou D., Bilali A., Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: A systematic review and meta-analysis. J. Hosp. Infect. 2021;108:120–134. doi: 10.1016/j.jhin.2020.11.008. - DOI - PMC - PubMed
    1. Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906. - DOI - PMC - PubMed
    1. Benenson S., Oster Y., Cohen M.J., Nir-Paz R. BNT162b2 mRNA COVID-19 Vaccine Effectiveness among Health Care Workers. N. Engl. J. Med. 2021;384:1775–1777. doi: 10.1056/NEJMc2101951. - DOI - PMC - PubMed

LinkOut - more resources